# Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07356466** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Fujian Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Gastric (Stomach) Cancer

## Interventions

- **DRUG:** Pucotenlimab Combined with Lenvatinib
- **DRUG:** Oxaliplatin plus S-1 regimen

## Key facts

- **NCT ID:** NCT07356466
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07356466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07356466, "Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07356466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*